Why Indivior Pharmaceuticals Stock Topped the Market Today

Indivior Pharmaceuticals (INDV) closed its merger with Supernus Pharmaceuticals (SUPN) on November 2, 2026, creating what the companies call a leading CNS biopharmaceutical company. The deal is done, and the combined business now trades as SUPN.

The terms matter for positioning. Indivior shareholders receive a $1 billion special cash dividend and will own approximately 56.5% of the merged company. That ownership split means Indivior holders, not legacy Supernus holders, control the majority of the new entity. Interpretation: the structure reads as a combination led by Indivior's shareholder base, even though the surviving company carries the Supernus name and ticker.

Management is targeting $125 million in annual cost synergies. The source gives no timeline for achieving them, so the pace of delivery is the open variable. Synergy targets of this size are typically where post-merger execution is judged (interpretation, not sourced fact).

The ticker consolidation also changes the trading picture. INDV no longer functions as a separate vehicle; exposure now runs through SUPN. Traders holding either name should treat the combined company as a new risk profile rather than extrapolate from pre-deal price action.